SS 15 - Immunotherapy Integration and Immuno Biomarkers Across Mucosal and Cutaneous SCC

Presentations

• 10:45am - 10:55am ET

  A Phase II, Multicenter, Single-Arm Clinical Trial of Response-Adapted Definitive Radiotherapy And CeMiPlimAb-Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART

  Speaker: Christopher Barker, MD - Memorial Sloan Kettering Cancer Center, New York
• 10:55am - 11:05am ET

  Phase 2 Trial of First-Line Camrelizumab plus Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Oral Squamous Cell Carcinoma: Outcomes and Toxicity Profile

  Speaker: Feng Liu, MD - Hunan Cancer Hospital, Changsha
• 11:05am - 11:15am ET

  C-Post Study of Adjuvant Cemiplimab for High-Risk Cutaneous Squamous Cell Carcinoma: Impact of Adjuvant Radiotherapy on Disease-Free Survival

  Speaker: Sandro Porceddu, MD - Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne
• 11:15am - 11:25am ET

  Secondary Immunological Analysis of a Prospective Trial in Patients with Recurrent Head and Neck Malignancies

  Speaker: Soumya Unnikrishnan, MD, MS - Winship Cancer Institute of Emory University, Atlanta
• 11:25am - 11:35am ET

  Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: 3-Year Follow-Up of the INSIGHT Study

  Speaker: Xiaomin Ou, MD - Fudan University Shanghai Cancer Center, Shanghai
• 11:35am - 11:45am ET

  Efficacy and Safety of an Adaptive Treatment Strategy for Locoregionally Advanced Nasopharyngeal Carcinoma Based on Response Stratification to Nimotuzumab Plus Induction Chemotherapy: A Prospective Multicenter Phase II Clinical Study

  Speaker: Lei Zeng, MD - The Second Affiliated Hospital of Nanchang University, Nanchang
• 11:45am - 11:55am ET

  Discussant

  Speaker: Richard Bakst, MD - Mount Sinai Health System and New York Proton Center, NEW YORK